Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409539 · ClinicalTrials.gov registry record · Phase 2
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 550
- Enrollment target
NCT00409539: Completed Phase 2 study, sponsored by Sumitomo Pharma America.
NCT00409539 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 550 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (314% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00409539, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 550 participants
- Enrollment target
Study Summary
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The hypothesis will be tested by measuring the change in mean voids/24 hrs after treatment with SMP-986 compared to placebo, as well comparing the change in: the severity of urgency episodes, mean number of urgency episodes/24 hr, mean number of incontinence episodes/24 hr and the mean void volume/void between SMP-986 and placebo.
Interventions
- DRUG Placebo
- DRUG SMP-986
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00409539 record still lists
NCT00409539 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (314% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00409539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00409539 about?
NCT00409539 is a clinical study titled "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)". SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The hypothesis will be tested by measu...
What is the current status of trial NCT00409539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 550 participants. The study started on 2006-12. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00409539?
The interventions under investigation include: Placebo (DRUG), SMP-986 (DRUG).
Who is sponsoring clinical trial NCT00409539?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00409539's enrollment target sits among peer trials
550 60th of 2000 higher than 1,939 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia